No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ARWR Arrowhead Pharmaceuticals
- 23.575
- -1.525-6.08%
Close Jun 18 16:00 ET
2.93BMarket Cap-5573P/E (TTM)
25.200High23.510Low838.96KVolume25.100Open25.100Pre Close20.01MTurnover0.76%Turnover RatioLossP/E (Static)124.20MShares39.83052wk High6.05P/B2.61BFloat Cap20.67052wk Low--Dividend TTM110.70MShs Float162.500Historical High--Div YieldTTM6.73%Amplitude1.200Historical Low23.850Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $90
H.C. Wainwright analyst Patrick Trucchio maintains $Arrowhead Pharmaceuticals(ARWR.US)$ with a buy rating, and maintains the target price at $90.According to TipRanks data, the analyst has a success r
Goldman Starts Arrowhead at Neutral, Cites RNAi Portfolio Validation
Arrowhead Pharmaceuticals Initiated at Neutral by Goldman Sachs
Arrowhead Pharmaceuticals Initiated at Neutral by Goldman Sachs
Arrowhead Pharmaceuticals Price Target Announced at $31.00/Share by Goldman Sachs
Arrowhead Pharmaceuticals Price Target Announced at $31.00/Share by Goldman Sachs
Goldman Sachs Initiates Arrowhead Pharmaceuticals(ARWR.US) With Hold Rating, Announces Target Price $31
Goldman Sachs analyst Andrea Tan initiates coverage on $Arrowhead Pharmaceuticals(ARWR.US)$ with a hold rating, and sets the target price at $31.According to TipRanks data, the analyst has a success r
Express News | Arrowhead Pharmaceuticals Inc : Leerink Partners Raises Target Price to $29 From $27
Comments
Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia
$Arrowhead Pharmaceuticals(ARWR.US$
$Arrowhead Pharmaceuticals(ARWR.US$
1
$Arrowhead Pharmaceuticals(ARWR.US$
Insiderd selling shares and financials dont look good. Im guessing they dont have anything in the pipeline?
Insiderd selling shares and financials dont look good. Im guessing they dont have anything in the pipeline?
The company's poor performance and the CEO's high pay, despite falling earnings and shareholder value, may upset shareholders. The upcoming AGM on March 14th is a chance for shareholders to hold the board and management accountable.
$Arrowhead Pharmaceuticals(ARWR.US$ why drop today?
$Arrowhead Pharmaceuticals(ARWR.US$ such a odd spot here
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg